Pain Analysis in Patients with Pancreatic Carcinoma: Irreversible Electroporation versus Cryoablation

Table 1

Clinical characteristics, complications, drug requirements, and pain scores of patients in the two groups.

Parameter	IRE	CRYO
Number of patients	22	26
Number of lesions	22	27
Number of sessions	25	31
Age (years)
Mean ± SD	62.00 ± 9.79	57.69 ± 12.86
Sex
Male	14 (63.64%)	18 (69.23%)
Female	8 (36.36%)	8 (30.77%)
ECOG performance status
0	1 (4.55%)	3 (11.54%)	0.8510
1	19 (86.36%)	21 (80.77%)
2	2 (9.09%)	2 (7.69%)
Adjuvant therapy
Yes	13 (59.09%)	17 (65.38%)
No	9 (40.91%)	9 (34.62%)
Concurrent drug therapy
Analgesics
Yes	3 (13.64%)	3 (11.54%)	0.7676
No	19 (86.36%)	23 (88.46%)
Psychotherapeutics
Yes	1 (4.55%)	4 (15.37%)	0.3569
No	21 (95.45%)	22 (84.62%)
Both
Yes	1 (4.55%)	3 (11.54%)	0.6142
No	21 (95.45%)	23 (88.46%)
Lesion diameter (cm)
Mean ± SD	5.25 ± 2.29	4.98 ± 2.13
Location
Head	12	15
Body/tail	10	11
Clinical stage
IIa	1 (4.55%)	2 (7.69%)	0.9600
IIb	4 (18.18%)	3 (11.54%)
III	14 (63.64%)	17 (65.38%)
IV	3 (13.64%)	4 (15.38%)
Complications
Present	3 (13.64%)	2 (7.69%)	0.6492
Absent	19 (86.36%)	24 (92.31%)
Hydromorphone provided (mg)
Mean ± SD	3.89 ± 1.35	3.97 ± 1.60
Pain score
Mean ± SD	4.95 ± 1.94	4.85 ± 2.07

values calculated by Fisher’s exact test; values calculated by Chi-square test; and values calculated by Student’s -test.